China Shineway Pharmaceutical Stock Net Income
| CSWYF Stock | USD 1.00 0.00 0.00% |
China Shineway Pharm technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
China Shineway's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing China Shineway's valuation are provided below:China Shineway Pharmaceutical does not presently have any fundamental signals for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. China |
China Shineway 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to China Shineway's pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of China Shineway.
| 11/13/2025 |
| 02/11/2026 |
If you would invest 0.00 in China Shineway on November 13, 2025 and sell it all today you would earn a total of 0.00 from holding China Shineway Pharmaceutical or generate 0.0% return on investment in China Shineway over 90 days. China Shineway is related to or competes with Kaken Pharmaceutical, Kossan Rubber, Luye Pharma, and Inventiva. China Shineway Pharmaceutical Group Limited, an investment holding company, engages in the research and development, man... More
China Shineway Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure China Shineway's pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess China Shineway Pharmaceutical upside and downside potential and time the market with a certain degree of confidence.
China Shineway Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for China Shineway's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as China Shineway's standard deviation. In reality, there are many statistical measures that can use China Shineway historical prices to predict the future China Shineway's volatility.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of China Shineway's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
China Shineway Pharm Backtested Returns
We have found three technical indicators for China Shineway Pharmaceutical, which you can use to evaluate the volatility of the firm. The firm shows a Beta (market volatility) of 0.0, which signifies not very significant fluctuations relative to the market. the returns on MARKET and China Shineway are completely uncorrelated.
Auto-correlation | 0.00 |
No correlation between past and present
China Shineway Pharmaceutical has no correlation between past and present. Overlapping area represents the amount of predictability between China Shineway time series from 13th of November 2025 to 28th of December 2025 and 28th of December 2025 to 11th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of China Shineway Pharm price movement. The serial correlation of 0.0 indicates that just 0.0% of current China Shineway price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.0 | |
| Spearman Rank Test | 1.0 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, China Shineway Pharmaceutical reported net income of 556.67 M. This is 63.11% higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The net income for all United States stocks is 2.51% higher than that of the company.
China Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses China Shineway's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of China Shineway could also be used in its relative valuation, which is a method of valuing China Shineway by comparing valuation metrics of similar companies.China Shineway is currently under evaluation in net income category among its peers.
China Fundamentals
| Return On Equity | 0.0964 | |||
| Return On Asset | 0.0492 | |||
| Profit Margin | 0.17 % | |||
| Operating Margin | 0.16 % | |||
| Current Valuation | 164.34 M | |||
| Shares Outstanding | 827 M | |||
| Shares Owned By Insiders | 66.30 % | |||
| Shares Owned By Institutions | 4.61 % | |||
| Price To Earning | 10.01 X | |||
| Price To Book | 0.90 X | |||
| Price To Sales | 0.24 X | |||
| Revenue | 3.22 B | |||
| Gross Profit | 2.41 B | |||
| EBITDA | 721.36 M | |||
| Net Income | 556.67 M | |||
| Cash And Equivalents | 4.21 B | |||
| Cash Per Share | 5.57 X | |||
| Total Debt | 14.91 M | |||
| Debt To Equity | 0 % | |||
| Current Ratio | 5.19 X | |||
| Book Value Per Share | 8.04 X | |||
| Cash Flow From Operations | 703.15 M | |||
| Earnings Per Share | 0.11 X | |||
| Number Of Employees | 3.87 K | |||
| Beta | 0.85 | |||
| Market Capitalization | 785.65 M | |||
| Total Asset | 7.2 B | |||
| Z Score | 31.2 | |||
| Annual Yield | 0.05 % | |||
| Net Asset | 7.2 B | |||
| Last Dividend Paid | 0.32 |
About China Shineway Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze China Shineway Pharmaceutical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of China Shineway using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of China Shineway Pharmaceutical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Other Information on Investing in China Pink Sheet
China Shineway financial ratios help investors to determine whether China Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in China with respect to the benefits of owning China Shineway security.